• Vivozon Pharmaceutical reset the conversion price on its 21st convertible bond to KRW 3,001 from KRW 4,827, effective Oct. 12, 2026.
• Adjustment raised shares issuable on the KRW 3 billion outstanding principal to 999,666 from 621,504.
• Reset was triggered by a drop in the stock’s market price, within a KRW 2,500 floor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivozon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012900381), on October 12, 2026, and is solely responsible for the information contained therein.